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Pancreatic cancer is the fourth leading cause of death by cancer in Europe and in the US1. In the US alone, it is 
estimated that over 55 000 new cases of pancreatic cancer will be diagnosed in 2018. he increasing incidence and 
death rates alarmingly suggest that it will become the second leading cause of cancer-related deaths before 20302,3. 
he current treatment protocols for patients with pancreatic cancer include surgery, with partial or total removal 
of the pancreas, radiation therapy, and mixed-drug chemotherapy, depending on the type and stage of the diag-
nosed cancer. Nonetheless, the 5-year survival rates for this fatal disease still remain at 9% in the US and 3% in 
Europe, with most patients succumbing to the disease between 4.6 months and 2 years ater diagnosis, clearly 
demonstrating the need to improve early diagnosis and to provide more efective and safer treatments. Pancreatic 
cancer is particularly hard to target because 67–100% of tumours contain on average 63 genetic mutations per 
cancer, involving the impressive number of 12 altered cellular signalling pathways and processes4. herefore, 
developing multifunctional compounds able to reach several relevant drug targets, that modulate entire regula-
tory networks or multiple pathways, being both preventive and therapeutic, is much more likely to serve as an 
efective treatment for this devastating disease5,6.
Nature is an important source for inding new anticancer drugs. Between 1981 and 2014, 83% of all approved 
small molecule anticancer drugs were either natural products or their derivatives or natural product mimicks7. 
Terpenoids are a large group of phytochemicals that have been explored as potential cytoprotective and chemopre-
ventive agents. According to several preclinical animal model studies, both naturally occurring and semi-synthetic 
terpenoids act at various stages of tumour development including inhibiting initiation and promotion of carcino-
genesis, inducing tumour cell diferentiation and apoptosis, and suppressing tumour angiogenesis8–13. For instance, 
two derivatives of the triterpenoid oleanolic acid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and 
2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid methyl ester (bardoxolone methyl or CDDO-Me), progressed 
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into phase I clinical trials for the treatment of leukaemia as well as solid tumours and lymphoid malignancies6,14,15. 
Highly oxygenated abietane-type diterpenoids such as triptolide and minnelide, and tanshinone A, have been stud-
ied for the treatment of pancreatic cancer16–20. Minnelide is a prodrug of triptolide with improved solubility and is 
currently being tested in clinical trials for advanced tumours including pancreatic cancer21,22.
Dehydroabietic acid (1, Fig. 1) is an aromatic abietane-type diterpenoid which has been reported to possess 
anticancer activities against several cancer types, and using it as a starting material in an attempt to improve its 
bioactive properties, a number of semi-synthetic derivatives have been produced19,20. However, to the best of 
our knowledge, very little is known about the potential efects of 1 and its derivatives against pancreatic cancer. 
More importantly, 1 is an agonist of the peroxisome proliferator-activated receptor γ (PPAR-γ) and suppresses 
the production of pro-inlammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1/CCL2), 
tumour necrosis factor α (TNF-α) and nitric oxide (NO), making it potentially relevant for the treatment of 
cancer-related inlammation23,24. hus, 1 is a highly promising molecular scafold for the development of innova-
tive multifunctional drugs for the treatment and prevention of cancer. Herein we report the design, synthesis and 
evaluation of 1 and a panel of its semisynthetic derivatives against pancreatic cancer cells. We tested the ability 
of the compounds to block inlammation and induce cancer diferentiation and carried out target deconvolution 
studies to propose a possible mode of action for the most promising compounds in the study.

 ?
Ǥ We irst tested our in-house library of oxidised derivatives of 1 (Fig. 1)25 for their potential to 
inhibit the proliferation of human Aspc-1 and mouse PanAsc 2159 pancreatic cancer cell lines using the MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Table 1). As the inlammatory process 
within the tumour microenvironment has been demonstrated to have a major role in the pathogenesis and pro-
gression of cancer26, we also tested the ability of the compounds to block the formation of NO, an important 
mediator of inlammation, using mouse macrophage-like cells (RAW 264.7) treated with various concentrations 
of the compounds and stimulated with interferon-γ (INFγ). he starting material 1 was inactive against all the 
tested cell lines, even when tested at the high concentration of 60 µM. Among the oxidised products we found 
that only 3 and 6, two ester derivatives bearing a carbonyl group at position 7 were active against the tested cell 
lines, yet none of the prepared compounds inhibited the production of pro-inlammatory NO, representing still a 
modest improvement in activity compared to the parent compound.
 ?Ǧ ?ǦǦƪƤ 
Ǥ A recent analysis revealed that 59% of all small-molecule drugs contain a nitrogen 
heterocycle, clearly demonstrating their relevance as privileged moieties among pharmaceuticals27. In this analy-
sis, the top three spots were ruled by pyridine, piperidine, and piperazine. Indeed, pyridyl groups tend to increase 
metabolic stability28 and have been used to improve the drug-like properties of natural products29. Moreover, 
pyridyl group additions to several terpenoids have resulted in an improvement of their anticancer properties28. 
herefore, we hypothesized that coupling of a nitrogen heterocycle to 1 could result in a set of compounds with 
improved bioactivity. Insertion of a pyridyl group at C7 of compounds 3, 6 and 10 was accomplished by Suzuki 
cross-coupling (Fig. 2) via the preparation of the corresponding vinyl trilate intermediates 11, 16 and 1930. he 
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preparation of 10 is depicted in Fig. 1 and proceeded via a two-step procedure for removal of the C13 isopropyl 
side chain of 4 to give 9, followed by methylation. Coupling of the heterocycle was made with bis(triphenylphos-
phine)palladium(II) dichloride and diethyl(3-pyridyl)borane, in the presence of base (Fig. 2)30. Compounds 12, 
17 and 20 were obtained in 63%, 74% and 61% yields, respectively, ater chromatographic puriication. Reduction 
of the ring A ester in 12 and 17 with LiAlH4 gave 13 and 18 whereas hydrolysis with KOH in a mixture of ethylene 
glycol and water (10:1) gave 21 and 14 that were further converted into 15 and 22 through carbodiimide coupling.
In this set of compounds, the esters 12 and 17, the alcohol 13 and the amide 15 were active against both 
pancreatic cell lines with IC50 values ranging from of 22.0 to 38.5 µM that correlated well with their ability to 
inhibit NO production in mouse macrophages (Table 1). he same efect was, however, not observed for the 
12-acetyl derivatives 21 and 22 and among the 12-substituted compounds prepared. Only 20 was active against 
mouse PanAsc 2159 cells with an IC50 value of 23.9 µM and could in addition block NO production within the 
same concentration range. he presence of a carboxyl group in ring A (14 and 21) had a negative impact on the 
anti-proliferative activity of these compounds; however, the ability to inhibit NO production was retained in 14. 
Overall, the presence of the pyridyl group proved advantageous for the activity of the compounds derivatised 
from the initial in-house set. Nonetheless, the observed potency was still in the high micromolar range and thus 
further synthetic eforts were placed to produce an additional set of compounds (Fig. 3).
 ?ǦǦƪ 
Ǥ Oximes are well-known to interfere with reactive oxygen species and many oximes 
and O-substituted oximes have been reported to have anti-inlammatory and anticancer properties, including 
against multi-drug resistant cancer cell lines31–33. Derivatives 20 (Fig. 2), 6 and 7 (Fig. 1), bearing a 12-acetyl 
group, were selected for further modiication by conversion of carbonyl groups into either a simple oxime or an 
O-substituted oxime of increasing bulkiness according to Fig. 3. Compounds 23–31 were synthesised via reaction 
with hydroxylamine hydrochloride or the corresponding O-alkyl hydroxylamine in the presence of pyridine.
Except for compound 28, which consists of a mixture of isomers, all other compounds were obtained as a 
single isomer ater chromatographic puriication. Introduction of an oxime at position 12 clearly increased the 
anti-proliferative activity against the pancreatic cancer cell lines as well as the inhibition of NO production, with 
and without the pyridyl group at position 7 (Table 1). Compound 26 displayed the most potent anti-inlammatory 
efects, with an IC50 value of 1.1 µM. In Aspc-1 cells, the IC50 values were reduced to low micromolar range in 
23 (8.6 µM) and 26 (8.9 µM). he introduction of bulkier oximes in 27, 28, 30 and 31 resulted in inactive com-
pounds. However, in the presence of the 7-pyridyl group, 24 and 25 showed improved activity in all assays with 
IC50 values ranging from 8.6 to 15.9 µM.

 ?Ǧ
 ? ?Ǧ ?Ǥ To deine whether the growth inhibitory properties of 
the compounds were associated with regulation of the cell cycle, western blot and cell cycle analyses were made 
with ive selected compounds from the in vitro assays namely, the oximes 23–26 and 29 (Fig. 4). PanAsc 2159 
Compounda
IC50 (µM)
PanAsc 2159b Aspc-1b NOc
3 28.3 ± 3.1 31.0 ± 0.4 N.A.d
5 N.A. 19.3 ± 1.8 N.A.
6 27.6 ± 5.0 22.5 ± 3.6 N.A.
12 22.9 ± 1.9 20.0 ± 2.4 23.0 ± 0.3
13 22.0 ± 2.3 20.3 ± 2.7 23.5 ± 0.2
14 N.A. N.A. 27.8 ± 0.7
15 34.0 ± 3.5 30.3 ± 3.6 31.2 ± 2.0
17 38.5 ± 7.1 35.9 ± 3.0 32.9 ± 0.6
20 23.9 ± 4.4 N.A. 29.9 ± 1.3
23 10.6 ± 3.0 8.6 ± 1.1 6.8 ± 1.6
24 15.9 ± 4.6 14.0 ± 1.1 12.2 ± 4.6
25 11.2 ± 3.5 8.6 ± 2.6 11.6 ± 1.6
26 14.8 ± 1.4 8.9 ± 1.2 1.1 ± 0.6
29 16.4 ± 1.1 13.1 ± 0.6 10.8 ± 2.8
Table 1. Anti-proliferative and anti-inlammatory activity screening of the compounds in this study. 
aCompounds 1, 4, 7, 9, 10, 18, 21, 22, 28, 27, 30 and 31 were inactive against all parameters measured at the 
highest concentration tested (60 µM). bIC50 = Concentration of compound that inhibits 50% of cellular growth. 
IC50 values were determined by MTT assay ater 72 hours of treatment. he values are the mean ± SD of at 
least three independent experiments. Pancreatic cancer cell lines: Aspc-1 (human) and PanAsc 2159 (mouse). 
cIC50 =Concentration of compound that inhibits the formation of NO by 50%. IC50 values were determined 
using RAW 246.7 mouse macrophage-like cells ater treatment with the compound for 20 minutes and 
stimulation with INFγ (10 ng/mL) for 24 hours. he values are the mean ± SD of at least three independent 
experiments. dN.A. = not active at 60 µM.
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and Aspc-1 cells were treated for 48 hours with the compounds and the protein expression of p27 and cyclin 
D1 was investigated. p27 is a cyclin-dependent kinase inhibitor that regulates the activity of cyclin-dependent 
kinases (CDKs). Low levels of p27 are generally associated with several cancers, including that of the pancreas34. 
he amount of cyclin D1 is important for the cells to progress from the G1 phase forward into S phase and start 
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copying their DNA. If the balance of stimulatory versus inhibitory signals is towards cell growth and division the 
amount of cyclin D1 increases which leads to its binding to CDK4 and CDK6. Overexpression of cyclin D1 is 
common in pancreatic cancer35,36.
he western blot analysis on PanAsc 2159 cells (Fig. 4B) revealed a dose-dependent down-regulation of cyclin 
D1 for and induction of p27 ater treatment with 23, 26, 29 however not with 24 and 25. Compound 1 did not 
afect any of the measured markers even at the high concentration of 20 µM. Aspc-1 cells (Fig. 4A) did not express 
cyclin D1 but p27 was up-regulated in a dose-dependent manner for all tested compounds apart from 1 where the 
efect was the opposite at 20 µM. he cell cycle analysis on Aspc-1 cells showed that with compounds 23–26 and 
29, especially at 10 µM concentration, the majority of the cells are in the G1 phase. he histogram (Fig. 4C) shows 
the results for compound 29 vs. control. In PanAsc 2159 cells (Fig. 4D) a similar trend is observed, although not 
so evident. hese indings support the results from the anti-proliferation assays and show that the growth inhib-
itory properties are likely due to cell cycle arrest in G1 phase, observed in the cell cycle analysis and expressed 
here as changed levels of cyclin D1 and p27. Of note, for compound 23, only 5 and 10 µM samples were included 
for the treatment of Aspc-1 cells in western blot analysis because at 20 µM many cells died. At this concentration, 
cleaved poly (ADP-ribose) polymerase (PARP) was clearly observed, suggesting that cells were dying by apoptosis 
(data not shown).
ơǤ Regulating cell diferentiation is highly 
desirable in the context of cancer prevention and treatment37. he ability to induce malignant cells to overcome 
Figure 4. Efects of compounds 23–26, 29 and 1 on the expression of cell cycle proteins p27 in Aspc-1 cells 
(A) and p27 and cyclin D1 in PanAsc 2159 cells (B). Blots have been grouped from diferent parts of the same 
gels. Full-length blots and multiple exposures are found in the Supplementary Information. For compound 
23, concentration 20 µM was cropped out (from Aspc-1 treatment) as there was not enough protein to get 
a comparable result (most cells died at 20 µM). Cell cycle analysis of pancreatic cancer cells treated with 29. 
Aspc-1 (C) and PanAsc 2159 (D) cells were treated with 29 at 5 and 10 µM for 48 hours. he histogram of one 
experiment is illustrated (results for all compounds are in the supporting info). Results for the diferent stages of 
cell cycle are indicated for 3–4 independent experiments (mean ± SEM). Ability of compounds 23–26, 29 and 1 
to induce cancer cell diferentiation in U937 cells alone (E) and ability of compounds 23 and 25 to induce cancer 
cell diferentiation in U937 cells in combination with bexarotene (F). *P < 0.05, **P < 0.01, ****P < 0.0001 vs. 
vehicle (DMSO) alone. Vinc: vinculin (loading control).
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their block of diferentiation in order to undergo apoptosis may circumvent the need for a direct cytotoxic efect 
of drugs and has been correlated with a higher possibility of achieving complete remission and cure. In order 
to evaluate the ability of the compounds to induce monocyte diferentiation, we used human leukaemia cells 
as a model and CD11b, a cell surface antigen, as a diferentiation biomarker. his marker is weakly expressed 
on leukaemia U937 cells but can be induced with various established diferentiation agents such as retinoids or 
rexinoids.
Ater 4 days of treatment with the compounds, the expression of CD11b was measured by low cytometry. 
As shown in Fig. 4, induction of the expression of CD11b occurred ater treatment with all compounds, in a 
dose-dependent manner, when compared with the control. Compound 29 was the most efficient in induc-
ing CD11b expression, which was particularly evident at 10 µM. Compounds 23 and 25 were also combined 
with bexarotene, the only FDA-approved rexinoid for the treatment of cutaneous T-cell lymphoma, which has 
well-established cell diferentiation and growth suppression efects38,39, to look for possible synergism. However, 
no synergistic efects were observed in combination with bexarotene.
 ? ? ? ?ȋ ?ȌǤ he oxime derivatives 23 
and 26, difering at the C7 position by the presence of the pyridyl group in 23, were screened against a compre-
hensive panel of 140 kinases at the International Centre for Kinase Proiling (ICKP), in Dundee, UK (Table S1, 
Supporting information). Neither compound was found to be a very potent kinase inhibitor as the maximum 
level of enzyme inhibition was 30–40% at the single concentration tested of 10 µM. However, 26 stood out as 
being able to inhibit a single kinase by 35%, namely p90 ribosomal S6 kinase 2 (RSK2), an AGC kinase of the RSK 
family40,41. Notably, concomitant inhibition of RSK1, one of the 4 known isoforms, was not observed. In contrast, 
the 7-pyridyl containing 23 displayed, in addition to RSK2 inhibition, comparable activity against of a few other 
kinases especially protein kinase PKBβ (also an AGC kinase), as well as inhibitor of nuclear factor kappa-B kinase 
β (IKKβ), mammalian sterile 20-like 2 (MST2), proto-oncogene tyrosine kinase protein (Src) and Bruton agam-
maglobulinemia tyrosine kinase (BTK).
RSKs 1–4 are important downstream mediators of the Ras-ERK signal transduction pathway which, when 
activated, phosphorylate many substrates, including p27, in both the cytoplasm and nucleus, resulting in cell dif-
ferentiation, survival, growth and proliferation40–42. RSK2 is abundant in the skeletal muscle, heart and pancreas, 
and associates with T-cell-restricted intracellular antigen-1 (TIA-1) to localize to stress granules upon oxidative 
stress. RSK2 can also be activated by phosphorylation on tyrosine residues in response to ibroblast growth factor 
(FGF) receptor and Src activation. Inhibition of RSKs has been implicated in prevention of cellular invasion and 
metastasis. Currently there are four classes of RSK inhibitors reported in the literature41–44. However, none is 
selective towards single enzyme isoforms and addressing isoform selectivity to diferentiate between the speciic 
role of each RSK in cancer remains a challenge. In this regard, the selective efect of compound 26 on RSK2 activ-
ity seems very promising. In addition, the loss of selectivity in 23 provides important preliminary data to small 
chemical modiications around the diterpenoid core that can greatly impact this parameter. hus, dehydroabietic 
oximes can be regarded as a new chemical class with potential to develop isoform-selective RSK inhibitors. In 
particular, concomitant inhibition of RSK2 and PKBβ will need to be tackled due to the speciic role of the latter 
in insulin signalling40.

Abietane-type diterpenoids such as 1 are excellent scaffolds to develop in search for innovative multifunc-
tional agents for cancer treatment and prevention. In this study, we revealed that dehydroabietic oximes in 
particular, have multiple desirable actions on cancer cells including anti-proliferative, anti-inlammatory and 
diferentiation-inducing efects. hese efects are mediated by depletion of cell cycle proteins such as cyclin D1 
and induction of key proteins typically downregulated in many cancers such as p27. Selective inhibition of the 
AGC kinase RSK2 was also observed, however modest. Nonetheless, this inding paves the way for future investi-
gations of this class of compounds as potential isoform-selective inhibitors of RSKs, which will help to shed light 
onto their speciic roles in cell death and survival. Taken together, our indings suggest that compounds such as 
dehydroabietic oximes are worth pursuing when searching for novel therapies for cancers such as those of the 
pancreas, where there is the need to target multiple pathways concomitantly for a better chance of therapeutic 
success.
Methods
Ǥ Commercially available reagents and solvents were used without further puriication. Reagents 
were obtained from Pfaltz & Bauer, Sigma Aldrich Co, VWR International Oy or Fluorochem Ltd. All reactions 
were monitored with thin layer chromatography (TLC) using Silica gel 60 F254 TLC plates. Flash column chro-
matography (FCC) was made with a Biotage High-Performance Flash Chromatography Sp4-system (Uppsala, 
Sweden) using a 0.1-mm path length low cell UV detector/recorder module (ixed wavelength: 254 nm), and 
10 g, 25 g or 50 g SNAP cartridges (10–50 mL/min low rate). Infra-red (IR) spectra were obtained using a Vertex 
70 (Bruker Optics Inc., MA, USA) FTIR instrument. he measurements were made with a horizontal attenuated 
total relectance (ATR) accessory (MIRacle, Pike Technology, Inc, WI, USA). he transmittance spectra were 
recorded at a 4 cm−1 resolution between 4000 and 600 cm−1 using the OPUS 5.5 sotware (Bruker Optics Inc., 
MA, USA). Nuclear magnetic resonance (NMR) spectra were obtained using a Varian Mercury Plus 300 spec-
trometer or Bruker Ascend 400 spectrometer, in CDCl3, with tetramethylsilane (TMS) as the internal standard. 
he chemical shits were reported in parts per million (ppm) and on the δ scale from tetramethylsilane (TMS) 
as an internal standard. he coupling constants J are quoted in Hertz (Hz). ESI-MS was performed by direct 
injection or UPLC-MS using a Synapt G2 HDMS (Waters, Milford MA, USA) instrument. Compounds 9–25 and 
27–31 are novel. he synthesis of compounds 2–7 was reported previously23.
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 ? ?ǦǦ ?ǦǦǦ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ?ȌǤ To a stirred solution of 4 (0.960 g, 
2.66 mmol) in dichloromethane (15 mL) was added 4-dimethylaminopyridine (DMAP, 195 mg, 1.60 mmol) and 
acetic anhydride (1.63 g, 16.0 mmol). he solution was stirred at room temperature for 24 h ater which it was 
diluted with diethyl ether (90 mL) and water was added (30 mL). he aqueous phase was extracted with diethyl 
ether (2 × 40 mL) and the combined organic phase was washed with water (40 mL) and brine (30 mL) and dried 
over anhydrous Na2SO4. Ater removal of the solvent under reduced pressure a crude compound 8 (1.32 g) was 
obtained. he crude product was dissolved in acetic acid (10 mL) and the temperature raised to 100 °C. Ater 
stirring the solution for 3 h, acetic acid was evaporated and water (30 mL) and diethyl ether (50 mL) were added. 
he aqueous phase was extracted with diethyl ether (2 × 35 mL) and the combined organic phase was washed 
with a saturated aqueous solution of NaHCO3 (25 mL), water (25 mL) and brine (20 mL) and dried over anhy-
drous Na2SO4. Ater removal of the solvent under reduced pressure, the resulting crude product was puriied by 
lash chromatography on silica gel using ethyl acetate in n-hexane (0 to 100%) as the eluent giving compound 
9 (510 mg, 63%) as a yellowish solid. 1H NMR (300 MHz, CDCl3) δ 1.24 (d, J = 0.7 Hz, 3 H), 1.34 (s, 3 H), 1.70 
(m, 6 H), 2.35 (m, 2 H), 2.71 (m, 2 H), 3.66 (s, 3 H), 5.87 (s, 1 H), 7.07 (dd, J = 8.6, 2.9 Hz, 1 H), 7.25 (d, J = 8.6 Hz, 
1 H), 7.52 (d, J = 2.9 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ 16.5, 18.3, 23.9, 36.8, 37.3, 37.4, 38.0, 44.2, 46.8, 52.4, 
113.0, 122.1, 125.3, 132.0, 148.3, 154.5, 178.1, 198.8. IR (ATR) 3375, 2947, 1722, 1666, 1605, 1440, 1221, 835 cm−1. 
HRMS m/z: calcd. for C25H32NO 303.1596 [M + H]
+, found 303.1597.
 ? ?ǦǦ ?ǦǦǦ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤ To a stirred solution of 9 
(61.6 mg, 0.204 mmol) and K2CO3 (70.4 mg, 0.509 mmol) in DMF (60 mL), MeI (25 µL, 0.41 mmol) was added. 
he solution was stirred at room temperature for 5 h. he solution was diluted with diethyl ether (20 mL) and a 
1 M aqueous solution of HCl (2 mL) was carefully added. he aqueous phase was extracted with diethyl ether 
(2 × 10 mL) and the combined organic phase was washed with a 1 M aqueous solution of HCl (10 mL), a saturated 
aqueous solution of NaHCO3 (10 mL), water (10 mL) and brine (10 mL) and dried over anhydrous Na2SO4. Ater 
removal of the solvent under reduced pressure, the resulting crude product was puriied by lash chromatogra-
phy on silica gel using ethyl acetate in n-hexane (0 to 100%) as the eluent giving compound 10 (57 mg, 88%) as a 
colourless oil. 1H NMR (400 MHz, CDCl3) δ 1.25 (s, 3 H), 1.34 (s, 3 H), 1.74 (m, 5 H), 2.34 (m, 2 H), 2.71 (m, 2 H), 
3.66 (s, 3 H), 3.83 (s, 3 H), 7.10 (dd, J = 8.7, 3.0 Hz, 1 H), 7.29 (d, J = 8.7 Hz, 1 H), 7.48 (d, J = 2.9 Hz, 1 H). 13C NMR 
(75 MHz, CDCl3) δ 16.5, 18.3, 23.9, 36.7, 37.3, 37.4, 37.9, 44.2, 46.8, 52.3, 55.6, 109.7, 122.2, 125.0, 131.9, 148.4, 
158.1, 165.6, 177.9, 198.2. IR (ATR) 2943, 1722, 1680, 1246, 1111, 1032, 829 cm−1. HRMS m/z: calcd. for C19H25O4 
317.1753 [M + H]+, found 317.1754.
 ?ǦȏȏȋȌȐȐǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤTo an 
argon-lushed lask with 3 (0.337 g, 1.03 mmol) in dichloromethane (10 mL) were added triluoromethanesulfonic 
anhydride (Tf2O, 209 µL, 1.24 mmol) and 2,6-di-tert-butyl-4-methylpyridine (DTBMP, 295 mg, 1.44 mmol) ater 
which temperature was raised to relux. he resulting solution was stirred for 3 h, at relux, ater which the solvent 
was evaporated and the residue was diluted with diethyl ether (60 mL) and water (25 mL). he aqueous phase 
was extracted with ethyl acetate (3 × 60 mL) and the combined organic phases were washed with a 1 M aqueous 
solution of HCl (2 × 30 mL), a saturated aqueous solution of NaHCO3 (2 × 30 mL), water (30 mL), and brine 
(30 mL), and dried over anhydrous Na2SO4. Ater removal of the solvent under reduced pressure, the resulting 
crude product was puriied by lash chromatography on silica gel using ethyl acetate in n-hexane (0 to 40%) as the 
eluent giving compound 11 (404 mg, 85%) as a colourless oil. 1H NMR (300 MHz, CDCl3) δ 1.15 (s, 3 H), 1.24 (d, 
J = 6.9 Hz, 6 H), 1.42 (s, 3 H), 1.75 (m, 6 H), 2.19 (m, 2 H), 2.90 (sept, J = 6.9 Hz, 1 H), 3.03 (d, J = 2.9 Hz, 1 H), 3.67 
(s, 3 H), 5.75 (d, J = 2.9 Hz, 1 H), 7.12 (d, J = 8.0 Hz, 1 H), 7.20 (dd, J = 8.0, 1.9 Hz, 1 H), 7.23 (d, J = 1.7 Hz, 1 H). 
13C NMR (75 MHz, CDCl3) δ 18.2, 18.4, 21.0, 23.8, 24.1, 33.9, 35.3, 35.6, 37.8, 46.3, 46.6, 52.4, 116.7, 119.6, 120.1, 
121.0, 122.3, 127.5, 128.3, 145.6, 145.9, 147.2, 177.8. IR (ATR) 2957, 1728, 1420, 1205, 1138, 1011, 827 cm−1. 
HRMS m/z: calcd. for C22H28O5SF3 461.1610 [M + H]
+, found 461.1610.
 ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤ To an argon-lushed lask with 11 (0.208 g, 
0.452 mmol) in THF (6 mL) were added bis(triphenylphosphine)palladium(II) dichloride (22.2 mg, 0.0316 mmol) 
and diethyl(3-pyridyl)borane (99.5 mg, 0.677 mmol). he temperature was raised to 45 °C and a 0.8 M aqueous 
solution of Na2CO3 (2.2 mL, 3.84 mmol) was added with vigorous stirring. he temperature was further raised 
to 75 °C and stirring continued for 3.5 h. Solvents were evaporated and the residue was diluted with diethyl ether 
(30 mL) and a 1 M aqueous solution of HCl was added (5 mL). he aqueous phase was extracted with diethyl 
ether (2 × 25 mL), and the combined organic phases were washed with a 1 M aqueous solution of HCl (10 mL), 
water (20 mL) and brine (10 mL), and dried over anhydrous Na2SO4. Ater removal of the solvent under reduced 
pressure, the resulting crude product was puriied by lash chromatography on silica gel using ethyl acetate in 
n-hexane (0 to 80%) as the eluent giving compound 12 (131 mg, 74%) as a white solid. 1H NMR (300 MHz, CDCl3) 
δ 1.16 (m, 9 H), 1.41 (s, 3 H), 1.79 (m, 6 H), 2.24 (m, 1 H), 2.77 (sept, J = 6.9 Hz, 1 H), 2.98 (d, J = 3.1 Hz, 1 H), 3.70 
(s, 3 H), 5.84 (d, J = 3.1 Hz, 1 H), 6.81 (d, J = 1.9 Hz, 1 H), 7.13 (dd, J = 8.0, 1.9 Hz, 1 H), 7.18 (d, J = 8.0 Hz, 1 H), 
7.31 (ddd, J = 7.9, 4.8, 0.9 Hz, 1 H), 7.66 (dt, J = 7.8, 2.0 Hz, 1 H), 8.60 (m, 2 H). 13C NMR (75 MHz, CDCl3) δ 18.2, 
18.5, 21.2, 24.0, 24.1, 33.8, 35.8, 35.8, 37.4, 46.4, 47.1, 52.2, 122.1, 123.2, 124.3, 126.2, 130.6, 132.7, 136.1, 136.4, 
136.8, 146.2, 146.5, 148.6, 149.8, 178.4. IR (ATR) 2953, 1724, 1223, 1124, 827, 808 cm−1. HRMS m/z: calcd. for 
C26H32NO2 390.2433 [M + H]
+, found 390.2437.
 ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤTo a suspension of lithium aluminium hydride 
(21.9 mg, 0.578 mmol) in anhydrous THF (2 mL) was added dropwise, at 0 °C, a solution of 12 (0.150 g, 
0.385 mmol) in anhydrous THF (2 mL). he suspension was stirred at room temperature for 2.5 h ater which 
the reaction mixture was quenched with methanol (1 mL). Solvents were evaporated and the residue was diluted 
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with diethyl ether (15 mL) and ethyl acetate (5 mL) and water (10 mL). Aqueous phase was extracted with diethyl 
ether (3 × 15 mL) and the combined organic phases were washed with water (3 × 15 mL) and dried over anhy-
drous Na2SO4. Ater removal of the solvent under reduced pressure, the resulting crude product was puriied 
by lash chromatography on silica gel using ethyl acetate in n-hexane (0–80%) as the eluent to give the product 
13 as a white solid (49 mg, 35%). 1H NMR (400 MHz, CDCl3) δ 1.04 (s, 3 H), 1.15 (m, 9 H), 1.50 (m, 2 H), 1.65 
(td, J = 12.7, 4.3 Hz, 1 H), 1.81 (m, 2 H), 1.98 (br. s, 1 H), 2.22 (dt, J = 12.7, 3.2 Hz, 1 H), 2.50 (d, J = 3.1 Hz, 1 H), 
2.77 (sept, J = 7.0 Hz, 1 H), 3.34 (d, J = 11.0 Hz, 1 H), 3.55 (d, J = 11.0 Hz, 1 H), 6.05 (d, J = 3.1 Hz, 1 H), 6.81 (d, 
J = 1.9 Hz, 1 H), 7.13 (dd, J = 8.0, 1.9 Hz, 1 H), 7.19 (d, J = 8.0 Hz, 1 H), 7.31 (dd, J = 7.9, 4.8 Hz, 1 H), 7.68 (dt, 
J = 7.8, 2.0 Hz, 1 H), 8.57 (dd, J = 4.9, 1.7 Hz, 1 H), 8.63 (d, J = 2.2 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ 18.4, 
18.5, 21.2, 24.0, 24.1, 33.8, 34.7, 36.2, 37.5, 37.6, 45.7, 71.7, 122.2, 123.2, 124.3, 126.2, 129.9, 132.8, 136.1, 136.9, 
137.0, 146.3, 146.8, 148.5, 149.7. IR (ATR) 3258 (br.), 2924, 1410, 1057, 808, 717 cm−1. HRMS m/z: calcd. for 
C25H32NO 362.2484 [M + H]
+, found 362.2487.
 ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤ A mixture of 12 (0.415 g, 1.07 mmol) and 
potassium hydroxide (0.179 g, 3.20 mmol) in ethylene glycol/water 10:1 (330 µL) was heated to 120 °C. Ater 
4.5 h, diethyl ether (30 mL) and water (20 mL) were added. he aqueous phase was extracted with diethyl ether 
(3 × 15 mL). Some of the product remained in the aqueous phase so the aqueous phase was acidiied with a 1 M 
aqueous solution of HCl and extracted again with diethyl ether (2 × 15 mL). he combined organic phases were 
washed with water (50 mL) and brine (40 mL) and dried over anhydrous Na2SO4. Ater removal of the solvent 
under reduced pressure, the resulting crude product was puriied by lash chromatography on silica gel using 
ethyl acetate in n-hexane (0 to 100%) as the eluent to give compound 14 as a white solid (337 mg, 84%). 1H NMR 
(300 MHz, CDCl3) δ 1.11 (m, 6 H), 1.19 (s, 3 H), 1.49 (s, 3 H), 1.81 (m, 6 H), 2.24 (d, J = 12.5 Hz, 1 H), 2.74 (sept, 
J = 6.9 Hz, 1 H), 3.07 (d, J = 3.1 Hz, 1 H), 6.14 (d, J = 3.1 Hz, 1 H), 6.73 (d, J = 1.9 Hz, 1 H), 7.11 (dd, J = 8.0, 1.9 Hz, 
1 H), 7.18 (d, J = 8.0 Hz, 1 H), 7.37 (ddd, J = 7.9, 5.0, 0.8 Hz, 1 H), 7.76 (dt, J = 7.9, 1.9 Hz, 1 H), 8.55 (dd, J = 4.9, 
1.6 Hz, 1 H), 8.77 (dd, J = 2.3, 0.8 Hz, 1 H).13C NMR (75 MHz, CDCl3) δ 18.5, 18.7, 21.3, 24.0, 24.1, 33.8, 36.0, 36.1, 
37.4, 45.9, 47.3, 122.2, 123.3, 124.0, 126.2, 132.6, 132.8, 135.4, 137.6, 137.7, 146.2, 146.3, 146.5, 148.1, 181.2. IR 
(ATR) 2926, 2478 (br.), 1909 (br.), 1699, 1263, 1128, 810, 713 cm−1. HRMS m/z: calcd. for C25H30NO2 376.2277 
[M + H]+, found 375. 376.2282.
 ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤCompound 14 (0.150 g, 0.399 mmol) was dis-
solved in DMF (2 mL) followed by the addition of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
hydrochloride (84.2 mg, 0.439 mmol) and 1-hydroxybenzotriazole (HOBt) monohydrate (59.3 mg, 0.439 mmol), 
at 0 °C. Ater stirring the solution for 5 min at 0 °C and 35 min at room temperature, a 25% aqueous solution of 
ammonia (154 µL, 1.00 mmol) was added. he reaction mixture was stirred for additional 23 h at room tem-
perature ater which the reaction was quenched with a mixture of water (10 mL) and ethyl acetate (20 mL). he 
aqueous phase was extracted with ethyl acetate (3 × 20 mL), and the combined organic phases were washed with 
a 1 M aqueous solution of HCl (2 × 20 mL), water (20 mL), and brine (20 mL) and dried over anhydrous Na2SO4. 
Ater removal of the solvent under reduced pressure, compound 15 (78 mg, 52%) was obtained as a white solid. 
1H NMR (300 MHz, CDCl3) δ 1.15 (m, 6 H), 1.19 (s, 3 H), 1.43 (s, 3 H), 1.79 (m, 6 H), 2.26 (m, 1 H), 2.77 (sept, 
J = 7.0 Hz, 1 H), 2.91 (m, 1 H), 5.78 (s, 2 H), 5.88 (d, J = 3.1 Hz, 1 H), 6.81 (d, J = 1.8 Hz, 1 H), 7.13 (dd, J = 8.0, 
1.8 Hz, 1 H), 7.18 (d, J = 8.0 Hz, 1 H), 7.31 (ddd, J = 7.8, 4.9, 0.9 Hz, 1 H), 7.68 (dt, J = 7.8, 1.9 Hz, 1 H), 8.58 (dd, 
J = 4.8, 1.7 Hz, 1 H), 8.62 (d, J = 1.9 Hz, 1 H).13C NMR (75 MHz, CDCl3) δ 18.3, 18.7, 21.2, 24.0, 24.1, 33.8, 35.8, 
36.9, 37.5, 46.1, 47.4, 122.1, 123.4, 124.4, 126.4, 130.1, 132.6, 136.4, 137.2, 146.2, 146.6, 148.3, 149.4, 181.0. IR 
(ATR) 3335, 3182, 2928, 1659, 808, 716 cm−1. HRMS m/z: calcd. for C25H31N2O 375.2436 [M + H]
+, found 
375.2436.
 ?ǦȏȏȋƪȌȐȐǦ ? ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧ
ȋ ? ?ȌǤ Following the procedure for compound 11, compound 16 was prepared from 10 (0.517 g, 1.63 mmol), 
Tf2O (333 µL, 1.98 mmol) and DTBMP (0.470 g, 2.29 mmol) in dichloromethane (16 mL). Compound 16: colour-
less oil (581 mg, 79%). 1H NMR (300 MHz, CDCl3) δ 1.13 (d, J = 0.7 Hz, 3 H), 1.41 (s, 3 H), 1.74 (m, 6 H), 2.18 (m, 
2 H), 3.02 (d, J = 2.9 Hz, 1 H), 3.68 (s, 3 H), 3.80 (s, 3 H), 5.79 (d, J = 2.9 Hz, 1 H), 6.86 (dd, J = 8.5, 2.7 Hz, 1 H), 
6.92 (d, J = 2.7 Hz, 1 H), 7.11 (d, J = 8.5 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ 18.2, 18.4, 21.2, 35.4, 35.6, 37.7, 
46.2, 46.8, 52.4, 55.5, 107.6, 115.6, 116.7, 120.5, 120.9, 123.6, 128.7, 140.5, 145.5, 158.3, 177.8. IR (ATR) 2947, 
1726, 1420, 1207, 1138, 1007, 825 cm−1. HRMS m/z: calcd. for C20H24O6SF3 449.1246 [M + H]
+, found 449.1248.
 ? ?ǦǦ ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?Ǧ Ǧ ? ?Ǧȋ ? ?ȌǤFollowing the pro-
cedure for compound 12, compound 17 was prepared from 16 (0.552 g, 1.23 mmol), (Ph3P)2PdCl2 (60.3 mg, 
0.0861 mmol), diethyl(3-pyridyl)borane (271 mg, 1.85 mmol) and 0.8 M Na2CO3 in H2O (5.9 mL, 4.72 mmol) in 
THF (16 mL). Compound 17: yellowish solid (292 mg, 63%). 1H NMR (400 MHz, CDCl3) δ 1.16 (s, 3 H), 1.41 
(s, 3 H), 1.79 (m, 5 H), 2.23 (d, J = 11.5 Hz, 1 H), 2.96 (d, J = 3.1 Hz, 1 H), 3.69 (s, 3 H), 3.70 (s, 3 H), 5.86 (d, 
J = 3.0 Hz, 1 H), 6.51 (d, J = 2.7 Hz, 1 H), 6.80 (dd, J = 8.6, 2.7 Hz, 1 H), 7.17 (d, J = 8.6 Hz, 1 H), 7.32 (ddd, J = 7.8, 
4.9, 0.8 Hz, 1 H), 7.67 (dt, J = 7.8, 2.0 Hz, 1 H), 8.59 (dd, J = 4.9, 1.7 Hz, 1 H), 8.61 (dd, J = 2.3, 0.8 Hz, 1 H). δ 13C 
NMR (75 MHz, CDCl3) δ 18.2, 18.5, 21.4, 35.9, 35.9, 37.2, 46.3, 47.3, 52.3, 55.4, 112.2, 113.1, 123.3, 123.4, 131.7, 
134.0, 136.3, 136.4, 136.7, 141.3, 147.9, 149.0, 157.8, 178.4. IR (ATR) 2939, 1722, 1221, 1030, 808, 717 cm−1. 
HRMS m/z: calcd. for C24H28NO3 378.2069 [M + H]
+, found 378.2069.
 ? ?ǦǦ ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ  ?ȌǤ Following the procedure for com-
pound 13, compound 18 was prepared from 17 (0.130 g, 0.344 mmol) and LiAlH4 (26.1 mg, 0.689 mmol) in THF 
(3.5 mL). Compound 18: white solid (42 mg, 35%). 1H NMR (400 MHz, CDCl3) δ 1.04 (s, 3 H), 1.17 (s, 3 H), 1.48 
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(m, 1 H), 1.65 (td, J = 12.6, 4.6 Hz, 2 H), 1.82 (m, 1 H), 2.21 (d, J = 12.6 Hz, 2 H), 2.48 (d, J = 3.1 Hz, 1 H), 3.34 (d, 
J = 11.1 Hz, 1 H), 3.55 (d, J = 11.1 Hz, 1 H), 3.69 (s, 3 H), 6.07 (d, J = 3.1 Hz, 1 H), 6.51 (d, J = 2.7 Hz, 1 H), 6.80 
(dd, J = 8.5, 2.7 Hz, 1 H), 7.18 (d, J = 8.5 Hz, 1 H), 7.31 (ddd, J = 7.8, 4.8, 0.9 Hz, 1 H), 7.68 (dt, J = 7.8, 2.0 Hz, 1 H), 
8.58 (dd, J = 4.8, 1.7 Hz, 1 H), 8.63 (d, J = 1.9 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ 18.4, 18.5, 21.4, 34.6, 36.3, 
37.4, 45.9, 55.4, 71.6, 112.2, 113.0, 123.2, 123.3, 130.7, 134.2, 136.2, 136.6, 136.7, 141.9, 148.5, 149.7, 157.7. IR 
(ATR) 3271 (br.), 2926, 1229, 1038, 808, 717 cm−1. HRMS m/z: calcd. for C23H28NO2 350.2120 [M + H]
+, found 
350.2120.
  ? ?ǦǦ ?ǦȏȏȋȌȐȐǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧ
ȋ ? ?ȌǤ Following the procedure for compound 11, compound 19 was prepared from 6 (1.00 g, 2.70 mmol), Tf2O 
(549 µL, 3.27 mmol) and DTBMP (0.776 g, 3.78 mmol) in dichloromethane (30 mL). Compound 19: yellowish oil 
(1.02 g, 75%). 1H NMR (300 MHz, CDCl3) δ 1.17 (s, 3 H), 1.23 (m, 6 H), 1.43 (s, 3 H), 1.80 (m, 6 H), 2.19 (m, 1 H), 
2.56 (s, 3 H), 3.05 (d, J = 2.9 Hz, 1 H), 3.37 (sept, J = 7.1 Hz, 1 H), 3.69 (s, 3 H), 5.86 (d, J = 2.9 Hz, 1 H), 7.23 (s, 
1 H), 7.39 (s, 1 H).13C NMR (75 MHz, CDCl3) δ 18.1, 18.4, 21.0, 23.8, 24.4, 29.4, 31.0, 35.2, 35.6, 37.8, 46.2, 46.5, 
52.5, 116.7, 120.3, 120.9, 121.4, 121.9, 129.7, 140.5, 145.1, 145.2, 145.9, 177.6, 203.4. IR (ATR) 2951, 1726, 1688, 
1421, 1207, 1140, 964 cm−1. HRMS m/z: calcd. for C24H30O6SF3 503.1715 [M + H]
+, found 503.1717.
 ? ?ǦǦ ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤFollowing the procedure for 
compound 12, compound 20 was prepared from 19 (0.252 g, 0.501 mmol), (Ph3P)2PdCl2 (24.6 mg, 0.0351 mmol), 
diethyl(3-pyridyl)borane (111 mg, 0.752 mmol) and 0.8 M Na2CO3 in H2O (2.4 mL, 1.93 mmol) in THF (7 mL). 
Compound 20: yellowish solid (132 mg, 61%). 1H NMR (400 MHz, CDCl3) δ 1.04 (d, J = 6.8 Hz, 3 H), 1.14 (d, 
J = 6.8 Hz, 3 H), 1.19 (s, 3 H), 1.42 (s, 3 H), 1.81 (m, 5 H), 2.26 (d, J = 11.9 Hz, 1 H), 2.59 (s, 1 H), 2.99 (d, J = 3.1 Hz, 
1 H), 3.38 (sept, J = 6.8 Hz, 1 H), 3.72 (s, 2 H), 5.97 (d, J = 3.1 Hz, 1 H), 7.00 (s, 1 H), 7.33 (s, 1 H), 7.36 (dd, J = 8.0, 
5.0 Hz, 1 H), 7.67 (dt, J = 7.9, 2.0 Hz, 1 H), 8.62 (m, 2 H). 13C NMR (75 MHz, CDCl3) δ 18.2, 18.4, 21.2, 24.0, 24.3, 
29.2, 30.9, 35.7, 35.8, 37.4, 46.2, 47.0, 52.3, 121.7, 123.5, 124.1, 132.8, 135.1, 135.9, 136.1, 136.5, 138.8, 145.5, 145.8, 
148.1, 148.9, 178.2, 203.5. IR (ATR) 2947, 1724, 1682, 1243, 1138, 716 cm−1. HRMS m/z: calcd. for C28H34 NO3 
432.2539 [M + H]+, found 432.2541.
 ? ?ǦǦ ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤ Following the procedure for com-
pound 14, compound 21 was prepared from 20 (0.450 g, 1.04 mmol) and KOH (176 mg, 3.13 mmol) in a mixture 
of ethylene glycol/water 10:1 (6.6 mL). Compound 21: yellowish solid (306 mg, 70%). 1H NMR (300 MHz, CDCl3) 
δ 0.98 (d, J = 6.8 Hz, 3 H), 1.12 (d, J = 6.8 Hz, 3 H), 1.21 (s, 3 H), 1.51 (s, 3 H), 1.84 (m, 6 H), 2.26 (d, J = 11.9 Hz, 
1 H), 2.58 (s, 3 H), 3.08 (d, J = 3.0 Hz, 2 H), 3.38 (sept, J = 6.7 Hz, 1 H), 6.28 (d, J = 3.1 Hz, 1 H), 6.92 (s, 1 H), 7.35 
(s, 1 H), 7.40 (dd, J = 8.0, 5.0 Hz, 1 H), 7.72 (dt, J = 7.9, 1.9 Hz, 1 H), 8.56 (dd, J = 5.0, 1.6 Hz, 1 H), 8.85 (dd, J = 2.2, 
0.8 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ 18.5, 18.6, 21.2, 23.9, 24.4, 29.1, 30.8, 35.8, 36.1, 37.3, 45.7, 47.1, 121.9, 
123.3, 123.8, 134.7, 135.0, 135.1, 137.1, 137.4, 138.5, 145.5, 146.1, 146.4, 148.1, 181.0, 203.5. IR (ATR) 2930, 2488 
(br.), 1911 (br.), 1682, 1238, 812, 714 cm−1. HRMS m/z: calcd. for C27H32NO3 418.2382 [M + H]
+, found 418.2386.
 ? ?ǦǦ ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤ Following the procedure for com-
pound 15, compound 22 was prepared from 21 (0.150 g, 0.358 mmol), EDC hydrochloride (75.3 mg, 0.393 mmol), 
HOBt monohydrate (53.1 mg, 0.393 mmol) and a 25% aqueous solution of ammonia (138 µL, 0.89 mmol) in DMF 
(2 mL). Compound 22: white solid (75 mg, 50%). 1H NMR (300 MHz, CDCl3) δ 1.03 (d, J = 6.8 Hz, 3 H), 1.14 (d, 
J = 6.8 Hz, 3 H), 1.21 (s, 3 H), 1.45 (s, 3 H), 1.85 (m, 6 H), 2.28 (d, J = 10.4 Hz, 1 H), 2.58 (s, 3 H), 2.96 (d, J = 3.2 Hz, 
1 H), 3.36 (sept, J = 6.9 Hz, 1 H), 5.68 (d, J = 66.4 Hz, 2 H), 6.01 (d, J = 3.1 Hz, 1 H), 6.99 (s, 1 H), 7.33 (m, 2 H), 7.66 
(dt, J = 7.8, 2.0 Hz, 1 H), 8.61 (m, 2 H). 13C NMR (75 MHz, CDCl3) δ 18.4, 18.6, 21.2, 23.9, 24.4, 29.3, 30.9, 35.7, 
36.9, 37.5, 46.1, 47.2, 121.6, 123.4, 124.2, 132.2, 135.2, 135.8, 136.2, 136.6, 138.8, 145.5, 145.8, 148.8, 149.5, 180.1, 
203.5. IR (ATR) 3341, 3182, 2928, 1666, 810, 715 cm−1. HRMS m/z: calcd. for C27H33N2O2 417.2542 [M + H]
+, 
found 417.2542.
 ? ?ǦǦ ?ǦǦǦ ?ǡ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤCompound 20 
(0.300 g, 0.695 mmol) was dissolved in EtOH (3 mL) followed by the addition of hydroxylamine hydrochloride 
(77.3 mg, 1.11 mmol) and pyridine (85 µL). he solution was stirred at relux for 2.5 h ater which solvents were 
evaporated and the resulting crude mixture was puriied by lash chromatography on silica gel using ethyl acetate 
in n-hexane (20 to 80%) as the eluent giving compound 23 (150 mg, 48%) as a white solid. 1H NMR (300 MHz, 
CDCl3) δ 1.03 (d, J = 6.9 Hz, 3 H), 1.12 (d, J = 6.8 Hz, 3 H), 1.17 (s, 3 H), 1.41 (s, 3 H), 1.80 (m, 6 H), 2.23 (m, 4 H), 
2.99 (m, 2 H), 3.70 (s, 3 H), 5.88 (d, J = 3.1 Hz, 1 H), 6.92 (s, 1 H), 7.03 (s, 1 H), 7.32 (ddd, J = 7.9, 4.9, 0.8 Hz, 1 H), 
7.66 (dt, J = 7.9, 1.9 Hz, 1 H), 8.61 (m, 3 H). 13C NMR (75 MHz, CDCl3) δ 16.9, 18.2, 18.4, 21.2, 24.2, 24.4, 29.9, 
35.7, 35.8, 37.4, 46.3, 47.0, 52.3, 122.2, 123.3, 123.5, 131.2, 133.2, 136.2, 136.4, 136.6, 144.3, 146.1, 148.6, 149.6, 
158.4, 178.4. IR (ATR) 2956, 1724, 1238, 1137, 922, 752, 714 cm−1. HRMS m/z: calcd. for C28H35N2O3 447.2648 
[M + H]+, found 447.2648.
 ? ?ǦǦ ?ǦǦǦ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤFollowing the proce-
dure for compound 23, compound 24 was prepared from 20 (0.250 g, 0.58 mmol), methoxyamine hydrochloride 
(77.4 mg, 0.927 mmol) and pyridine (71 µL) in EtOH (3.1 mL). Compound 24: yellowish solid (62 mg, 23%). 1H 
NMR (300 MHz, CDCl3) δ 1.04 (d, J = 6.9 Hz, 3 H), 1.14 (d, J = 6.8 Hz, 3 H), 1.17 (s, 3 H), 1.41 (s, 3 H), 1.81 (m, 
6 H), 2.18 (s, 3 H), 2.21 (m, 1 H), 2.98 (m, 2 H), 3.69 (s, 3 H), 3.97 (s, 3 H), 5.88 (d, J = 3.1 Hz, 1 H), 6.92 (s, 1 H), 
7.02 (s, 1 H), 7.32 (dd, J = 7.8, 4.7 Hz, 1 H), 7.63 (dt, J = 7.8, 1.8 Hz, 1 H), 8.59 (m, 2 H). 13C NMR (75 MHz, CDCl3) 
δ 17.4, 18.2, 18.4, 21.1, 24.2, 24.3, 30.0, 35.7, 35.8, 37.4, 46.3, 47.0, 52.3, 61.9, 122.2, 123.3, 123.6, 131.1, 133.2, 
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136.0, 136.1, 136.4, 136.6, 144.2, 146.1, 148.6, 149.6, 157.3, 178.4. IR (ATR) 2934, 1724, 1240, 1138, 1045, 864, 
715 cm−1. HRMS m/z: calcd. for C28H35N2O3 461.2804 [M + H]
+, found 461.2804.
 ? ?ǦǦ ?ǦǦǦ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤFollowing the procedure 
for compound 23, compound 25 was prepared from 20 (0.100 g, 0.23 mmol), O-benzylhydroxylamine hydro-
chloride (59.0 mg, 0.37 mmol) and pyridine (28 µL) in EtOH (1 mL). Compound 25: white solid (27 mg, 21%). 
1H NMR (300 MHz, CDCl3) δ 0.95 (d, J = 6.9 Hz, 3 H), 1.04 (d, J = 6.8 Hz, 3 H), 1.16 (s, 3 H), 1.40 (s, 3 H), 1.78 
(m, 6 H), 2.23 (s, 3 H), 2.94 (m, 2 H), 3.70 (s, 3 H), 5.21 (s, 2 H), 5.87 (d, J = 3.1 Hz, 1 H), 6.90 (s, 1 H), 7.00 (s, 1 H), 
7.36 (m, 5 H), 7.62 (dt, J = 7.9, 1.9 Hz, 1 H), 8.59 (m, 2 H). 13C NMR (75 MHz, CDCl3) δ 17.7, 18.2, 18.4, 21.1, 24.0, 
24.3, 29.8, 35.7, 35.8, 37.4, 46.3, 47.0, 52.2, 76.0, 122.2, 123.2, 123.6, 127.8, 128.2, 128.4, 131.1, 133.2, 136.0, 136.1, 
136.5, 136.5, 138.6, 144.3, 146.0, 148.7, 149.7, 157.8, 178.3. IR (ATR) 2928, 1724, 1238, 1138, 1024, 914, 858, 735, 
716, 698 cm−1. HRMS m/z: calcd. for C35H41N2O3 537.3117 [M + H]
+, found 537.3117.
 ? ?ǦǦǦ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤ Following the procedure for com-
pound 23, compound 26 was prepared from 7 (0.200 g, 0.561 mmol), hydroxylamine hydrochloride (62.4 mg, 
0.898 mmol) and pyridine (69 µL) in EtOH (2.4 mL). Compound 26: white solid (168 mg, 81%). 1H NMR 
(400 MHz, CDCl3) δ 1.20 (m, 9 H), 1.27 (s, 3 H), 1.42 (m, 1 H), 1.51 (td, J = 12.6, 4.1 Hz, 1 H), 1.76 (m, 5 H), 2.19 
(s, 3 H), 2.22 (dd, J = 12.6, 2.2 Hz, 1 H), 2.28 (d, J = 12.6 Hz, 1 H), 2.89 (m, 2 H), 2.99 (sept, J = 6.8 Hz, 1 H), 3.66 (s, 
3 H), 6.96 (s, 1 H), 7.01 (s, 1 H). 13C NMR (75 MHz, CDCl3) δ 16.7, 17.1, 18.7, 21.8, 24.4, 24.5, 25.2, 29.7, 29.9, 36.8, 
37.1, 38.1, 44.9, 47.8, 52.1, 124.2, 126.3, 134.5, 135.8, 143.6, 147.1, 158.8, 179.2. IR (ATR) 3225, 2930, 1724, 1244, 
905, 756 cm−1. HRMS m/z: calcd. for C21H27O3 327.2539 [M + H]
+, found 327.2542.
 ? ?ǦǦǦ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤ Following the procedure for com-
pound 23, compound 27 was prepared from 7 (0.200 g, 0.561 mmol), methoxylamine hydrochloride (61.9 mg, 
0.898 mmol) and pyridine (68 µL) in EtOH (2.3 mL). Compound 27: white solid (88.3 mg, 39%). 1H NMR 
(400 MHz, CDCl3) δ 1.20 (m, 9 H), 1.27 (s, 3 H), 1.41 (m, 1 H), 1.52 (td, J = 12.5, 4.2 Hz, 1 H), 1.74 (m, 5 H), 
2.14 (s, 3 H), 2.21 (dd, J = 12.6, 2.3 Hz, 1 H), 2.28 (d, J = 12.6 Hz, 1 H), 2.88 (dd, J = 9.1, 4.7 Hz, 2 H), 3.01 (sept, 
J = 6.9 Hz, 1 H), 3.65 (s, 3 H), 3.94 (s, 3 H), 6.96 (s, 1 H), 7.00 (s, 1 H).13C NMR (101 MHz, CDCl3) δ 16.6, 17.5, 
18.6, 21.7, 24.3, 24.4, 25.1, 29.7, 29.8, 36.7, 37.0, 38.0, 44.8, 47.7, 52.0, 61.7, 124.0, 126.3, 134.4, 135.7, 143.5, 146.9, 
157.5, 179.1. IR (ATR) 2928, 1720, 1437, 1246, 1049, 862 cm−1. HRMS m/z: calculated for C24H36NO3 386.2695 
[M + H]+ found 386.2697.
 ? ?ǦǦǦ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤ Following the procedure for com-
pound 23, compound 28 was prepared from 7 (0.150 g, 0.421 mmol), O-benzylhydroxylamine hydrochloride 
(107 mg, 0.673 mmol) and pyridine (53 µL) in EtOH (2 mL). Compound 28: colourless oil (142 mg, 73%, insepa-
rable mixture of two isomers in a ratio of 0.8:10). 1H NMR (400 MHz, CDCl3) δ 1.11 (m, 6 H), 1.20 (s, 3 H), 1.27 
(s, 3 H), 1.41 (m, 1 H), 1.52 (dd, J = 12.6, 4.2 Hz, 1 H), 1.74 (m, 5 H), 2.19 (m, 4 H), 2.26 (d, J = 12.7 Hz, 1 H), 2.89 
(m, 3 H), 3.66 (s, 3 H), 5.19 (s, 2 H), 6.93 (s, 1 H), 6.98 (s, 1 H), 7.36 (m, 5 H). 13C NMR (75 MHz, CDCl3) δ 16.7, 
17.9, 18.7, 21.7, 24.3, 24.4, 25.2, 29.6, 29.9, 36.8, 37.1, 38.1, 44.9, 47.8, 52.0, 75.8, 124.1, 126.4, 127.7, 128.2, 128.4, 
134.5, 135.7, 138.7, 143.6, 147.0, 158.0, 179.2. IR (ATR) 2930, 1724, 1244, 1109, 1024, 754, 698 cm−1. HRMS m/z: 
calcd. for C23H28NO2 462.3008 [M + H]
+, found 462.3008.
 ?ǡ ? ?ǦȋȌǦǦ ?ǡ ? ?ǡ ? ?ǦǦ ? ? ȋ ? ?ȌǤ Following the procedure for 
compound 23, compound 29 was prepared from 6 (0.150 g, 0.405 mmol), hydroxylamine hydrochloride (0.0900 g, 
1.30 mmol) and pyridine (98 µL) in EtOH (3 mL). Compound 29: white solid (168 mg, 81%). 1H NMR (400 MHz, 
CDCl3) δ 1.13 (s, H), 1.25 (dd, J = 14.8, 6.8 Hz, 6 H), 1.37 (s, 3 H), 1.71 (m, 5 H), 2.22 (s, 3 H), 2.30 (m, 2 H), 2.65 
(m, 2 H) 3.03 (sept, J = 6.8 Hz, 1 H), 3.65 (s, 3 H), 7.06 (s, 1 H), 7.81 (s, 1 H), 8.49 (brs, 2 H).13C NMR (75 MHz, 
CDCl3) δ 16.7, 17.0, 18.2, 23.1, 23.9, 24.3, 24.4, 30.1, 36.8, 37.2, 37.3, 41.8, 46.7, 52.3, 122.0, 123.1, 129.7, 138.1, 
144.6, 148.7, 155.4, 158.5, 178.4. IR (ATR) 3175 (br.), 2956, 1724, 1244, 943, 752 cm−1. HRMS m/z: calcd. for 
C23H33N2O4 401.2440 [M + H]
+, found 401.2441.
 ?ǡ ? ?ǦȋȌǦǦ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤ Following the procedure for 
compound 23, compound 30 was prepared from 6 (0.324 g, 0.875 mmol), methoxyamine hydrochloride (0.193 g, 
2.80 mmol) and pyridine (212 µL) in EtOH (3.6 mL). Compound 30: white solid (101 mg, 27%). 1H NMR 
(400 MHz, CDCl3) δ 1.11 (s, 3 H), 1.25 (dd, J = 15.5, 6.8 Hz, 6 H), 1.35 (s, 3 H), 1.70 (m, 5 H), 2.15 (s, 3 H), 2.26 
(m, 2 H), 2.55 (m, 2 H), 3.02 (sept, J = 6.8 Hz, 1 H), 3.64 (s, 3 H), 3.96 (s, 3 H), 4.01 (s, 3 H), 7.02 (s, 1 H), 7.86 (s, 
1 H). 13C NMR (101 MHz, CDCl3) δ 16.7, 17.5, 18.2, 23.0, 24.3, 24.3, 24.4, 30.2, 36.6, 37.2, 37.2, 41.7, 46.7, 52.2, 
61.9, 62.2, 122.0, 122.9, 129.7, 137.9, 144.4, 148.4, 153.8, 157.5, 178.4. IR (ATR) 2935, 1726, 1242, 1045, 893 cm−1. 
HRMS m/z: calculated for C25H37N2O4 429.2753 [M + H]
+ found 429.2749.
 ?ǡ ? ?ǦȋȌǦǦ ?ǡ ? ?ǡ ? ?ǦǦ ? ?Ǧȋ ? ?ȌǤFollowing the procedure for 
compound 23, compound 31 was prepared from 6 (0.150 g, 0.422 mmol), O-benzylhydroxylamine hydrochlo-
ride (216 mg, 1.35 mmol) and pyridine (102 µL) in EtOH (1.75 mL). Compound 31: white solid (105 mg, 45%). 
1H NMR (400 MHz, CDCl3) δ 1.09 (s, 3 H), 1.12 (d, J = 6.8 Hz, 3 H), 1.18 (d, J = 6.8 Hz, 3 H), 1.33 (s, 3 H), 1.69 
(m, 5 H), 2.20 (s, 3 H), 2.26 (m, 2 H), 2.59 (m, 2 H), 2.93 (sept, J = 6.8 Hz, 1 H), 3.61 (s, 3 H), 5.20 (s, 2 H), 5.24 (s, 
2 H), 6.99 (s, 1 H), 7.36 (m, 10 H), 7.83 (s, 1 H). 13C NMR (101 MHz, CDCl3) δ 16.7, 17.8, 18.2, 23.1, 24.2, 24.3, 
24.5, 30.0, 36.6, 37.2, 41.8, 46.7, 52.2, 76.0, 76.5, 122.2, 122.9, 127.8, 127.9, 128.2, 128.4, 128.4, 129.8, 137.9, 138.3, 
138.5, 144.4, 148.4, 154.2, 157.9, 178.4. IR (ATR) 2928, 1722, 1246, 1013, 906, 731 cm−1. HRMS m/z: calculated 
for C37H45N2O4 581.3379 [M + H]
+ found 581.3381.
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Ǥ U937 cells were cultured in RPMI 1640 supplemented with 5% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin, at 37 °C and 5% CO2. RAW 264.7 and PanAsc 2159 cells were grown in DMEM/10% 
FBS/1% penicillin-streptomycin. Aspc-1 cells were cultured in RPMI 1640 supplemented with 10% FBS and 1% 
penicillin-streptomycin.
Ǥ RAW 264.7 cells were plated in 96-well plates 2 × 105 per well. he next day, cells were treated with 
various concentrations of compounds for 20 min, and then stimulated with 10 ng/mL of interferon-γ for a total of 
24 h. Twenty-four hours later NO production was measured in the medium as nitrite using the Griess reaction45, 
and plates were read at 550 nm.
Ǥ Aspc-1 or PanAsc 2159 cells were plated in 96-well plates, 2500 cells/well for PanAsc 2159 and 
3000 cells/well for Aspc-1. he next day, cells were treated with various concentrations of compounds and incu-
bated for 72 h. hen, MTT solution (thiazolyl blue tetrazolium bromide, M5655, Sigma-Aldrich, St. Louis, MO) 
at 10 mM in PBS, pH 7.4 was added to each well and cells were incubated for 3 h. he supernatant was removed 
and a developing solution (0.04 M HCl in isopropanol) was added. Plates were read at 630–570 nm. 100% of cell 
viability was considered for control cells.
	Ǥ Monocytic diferentiation was evaluated in U937 cells, which were treated with the com-
pounds for 4 days and then stained for 30 min with a CD11b-FITC monoclonal antibody from BD Pharmingen. 
Cells were resuspended in 500 µL PBS/BSA/sodium azide prior to FACS analysis using LSRII-Diva 6.2 (BD). he 
geometric mean for each sample was determined using FlowJo V10.0 7r2 sotware (Tree Star).
Ǥ Aspc-1 or PanAsc 2159 cells were plated 2.5 × 105 or 2.0 × 105 per 100 mm3 dish and treated 
the next day with three diferent concentrations of the compounds for 48 h. Proteins were extracted with RIPA 
lysis bufer supplemented with protease inhibitors (1 mM phenylmethylsulfonyl luoride, 10 µg/mL leupeptin, 
50 µg/mL aprotinin), and concentrations were determined using the bicinchoninic acid (BCA) assay (Sigma). 
10–15 micrograms of proteins were resolved on 7.5% or 10% SDS-polyacrylamide gels. Goat anti-rabbit lgG 
HRP (horseradish peroxidase)-conjugated secondary antibody was purchased from Santa Cruz Biotechnology; 
cyclin D1, p27 and vinculin antibodies were obtained from Cell Signaling Technology. Developing images: GE 
Detection reagent 1 and 2, Fisher Scientiic Supersignal west femto luminol enhancer solution and West Femto 
Stable Peroxide bufer.
 Ǥ Cell cycle was assessed by flow cytometry using a fluorescence-activated cell sorter 
(FACS-BD-LSRII). PanAsc 2159 and Aspc-1 cells were treated with compounds 1, 23, 24, 25, 26 and 29 at 5 and 
10 µM for 48 hours, ixed in ice-cold 70% ethanol overnight and treated with PI (Biolegend, 10 µg/mL)/RNase 
(Worthington, 0.1 mg/mL) solution (40 minutes at 37 °C). DNA content was quantiied by low cytometry. Data 
was analyzed in FlowJo x.10.0.7r2 sotware (Tree Star).
Ǥ Results are described as mean ± SD unless otherwise noted on the igure legend. Results 
were analyzed using one-way ANOVA followed by the Dunnett’s multiple comparisons test (GraphPad Prism 
7.0). *, P < 0.05 was considered statistically signiicant.
Ǥ he kinase screening was performed with a radioactive ilter binding assay using 33P ATP 
by the International Centre for Kinase Profiling (ICKP). Detailed description of the protocol is reported 
elsewhere46,47.

he datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.

 1. Carrato, A. et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and 
costs. J. Gastrointest. Cancer 46, 201–211 (2015).
 2. Rahib, L. et al. Projecting cancer incidence and deaths to 2030: he unexpected burden of thyroid, liver, and pancreas cancers in the 
United States. Cancer Res. 74, 2913–2921 (2014).
 3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 68, 7–30 (2018).
 4. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 
(2008).
 5. Liby, K. T., Yore, M. M. & Sporn, M. B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of 
cancer. Nat. Rev. Cancer 7, 357–369 (2007).
 6. Liby, K. T. & Sporn, M. B. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention 
and treatment of chronic disease. Pharmacol. Rev. 64, 972–1003 (2012).
 7. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79, 629–661 (2016).
 8. Tran, K. et al. he combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in 
mouse models of cancer. Carcinogenesis 34, 199–210 (2013).
 9. Sporn, M. B. et al. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inlammatory 
and oxidative stress. J. Nat. Prod. 74, 537–545 (2011).
 10. hoppil, R. J. & Bishayee, A. Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World J Hepatol 3, 
228–249 (2011).
 11. Rabi, T. & Gupta, S. Dietary terpenoids and prostate cancer chemoprevention. Front. Biosci. 13, 3457–69 (2008).
 12. Patlolla, J. M. R. & Rao, C. V. Triterpenoids for cancer prevention and treatment: current status and future prospects. Curr. Pharm. 
Biotechnol. 13, 147–155 (2012).
www.nature.com/scientificreports/
1 2SCIENTIFIC REPORTS |         (2018) 8:15923 ȁǣ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
 13. Tong, L. et al. The mechanisms of carnosol in chemoprevention of ultraviolet B-light-Induced Non-Melanoma Skin Cancer 
Formation. Sci. Rep. 8, 3574 (2018).
 14. Hong, D. S. et al. A phase I irst-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin. 
Cancer Res. 18, 3396–3406 (2012).
 15. Dezube, B. J. et al. Interim results of a phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in 
patients with solid tumors and lymphoid malignancies (Abstract). J. Clin. Oncol. 25, 14101–14101 (2007).
 16. Phillips, P. A. et al. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 67, 9407–9416 
(2007).
 17. Chugh, R. et al. A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer. Sci. Transl. Med. 4, 156ra139 
(2012).
 18. Fronza, M. et al. In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia 
sahendica. Bioorg. Med. Chem. 19, 4876–4881 (2011).
 19. Xing, Y. et al. Anticancer efects of a novel class rosin-derivatives with diferent mechanisms. Bioorg. Med. Chem. Lett. 23, 3868–3872 
(2013).
 20. González, M. A. Synthetic derivatives of aromatic abietane diterpenoids and their biological activities. Eur. J. Med. Chem. 87, 
834–842 (2014).
 21. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03117920 (last accessed Aug 2018).
 22. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03129139 (last accessed Aug 2018).
 23. Kang, M. S. et al. Dehydroabietic acid, a phytochemical, acts as ligand for PPARs in macrophages and adipocytes to regulate 
inlammation. Biochem. Biophys. Res. Commun. 369, 333–338 (2008).
 24. Jang, H. J. & Yang, K.-S. Inhibition of nitric oxide production in RAW 264.7 macrophages by diterpenoids from Phellinus pini. Arch. 
Pharmacal Res. 34, 913–7 (2011).
 25. Kolsi, L. E. et al. Regioselective benzylic oxidation of aromatic abietanes: application to the semisynthesis of the naturally occurring 
picealactones A, B and C. ChemistrySelect 2, 7008–7012 (2017).
 26. Albini, A. & Sporn, M. B. he tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 7, 139–147 (2007).
 27. Vitaku, E., Smith, D. T. & Njardarson, J. T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen 
heterocycles among U.S. FDA approved pharmaceuticals. J. Med. Chem. 57, 10257–10274 (2014).
 28. Cao, M. et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol. Res. 
100, 135–147 (2015).
 29. DeCorte, B. L. Underexplored opportunities for natural products in drug discovery. J. Med. Chem. 59, 9295–9304 (2016).
 30. Moreira, V. M., Salvador, J. A. R., Simões, S., Destro, F. & Gavioli, R. Novel oleanolic vinyl boronates: synthesis and antitumor 
activity. Eur. J. Med. Chem. 63, 46–56 (2013).
 31. Rappoport, Z. & Liebman, J. F. he chemistry of hydroxylamines, oximes and hydroxamic acids. (Wiley, 2009).
 32. Qin, H.-L. et al. Synthesis of α, β-unsaturated carbonyl-based compounds, oxime and oxime ether analogs as potential anticancer 
agents for overcoming cancer multidrug resistance by modulation of elux pumps in tumor cells. J. Med. Chem. 59, 3549–3561 
(2016).
 33. van Dijk, J. & Zwagemakers, J. M. A. Oxime ether derivatives, a new class of nonsteroidal anti-inlammatory compounds. J. Med. 
Chem. 20, 1199–1206 (1977).
 34. Chu, I. M., Hengst, L. & Slingerland, J. M. he Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer 
therapy. Nat. Rev. Cancer 8, 253–267 (2008).
 35. Biliran, H. et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in 
an elastase-myc transgene-expressing pancreatic tumor cell line. Clin. Cancer Res. 11, 6075–6086 (2005).
 36. Gansauge, S. et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 57, 
1634–1637 (1997).
 37. Nowak, D., Stewart, D. & Koeler, H. P. Diferentiation therapy of leukemia: 3 Decades of development. Blood 113, 3655–3665 
(2009).
 38. Pileri, A., Delino, C. & Vieri Grandi, N. P. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and 
immunological sides. Immunotherapy 5, 427–433 (2013).
 39. Lehmann, J. M. Retinoids selective for retinoid X receptor response pathways. Science 258, 1944–1946 (1992).
 40. Arencibia, J. M. et al. AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the 
treatment of human diseases. Biochimic. Biophys. Acta 1834, 1302–1321 (2013).
 41. Romeo, Y. at al. Regulation and function of the RSK family of protein kinases. Biochem. J. 441, 553–569 (2012).
 42. Anjum, R. et al. he RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 9, 747–758 (2008).
 43. Jain, R. et al. Discovery of potent and selective RSK inhibitors as biological probes. J. Med. Chem. 58, 6766–6783 (2015).
 44. Ludwik, K. A. et al. Development of a RSK inhibitor as a novel therapy for triple-negative breast cancer. Mol. Cancer her. 15, 
2598–2608 (2016).
 45. Suh, N. et al. Novel Triterpenoids Suppress Inducible Nitric Oxide Synthase (iNOS) and Inducible Cyclooxygenase (COX-2) in 
Mouse Macrophages. Cancer Res. 58, 717–723 (1998).
 46. Bain, J. et al. he selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315 (2007).
 47. Hastie, C. J., McLauchlan, H. J. & Cohen, P. Assay of protein kinases using radiolabeled ATP: a protocol. Nat. Protoc. 1, 968–971 
(2006).

L.K., V.M.M. and J.Y.-K. acknowledge the University of Helsinki Research Foundation and the Academy of 
Finland (Projects 264020 and 265481) for inancial support.

V.M.M., K.L. and J.Y.-K. conceived the experiment(s), analysed the data and reviewed the manuscript. L.K. and 
A.L. conducted the experiment(s), analysed the data and wrote the manuscript.

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-34131-1.
Competing Interests: he authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional ailiations.
www.nature.com/scientificreports/
13SCIENTIFIC REPORTS |         (2018) 8:15923 ȁǣ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. he images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© he Author(s) 2018
